Comparison of two protocols of subthreshold micropulse yellow laser treatment for non-resolving central serous chorioretinopathy

Purpose: To study the effect of subthreshold micropulse yellow laser treatment on central serous chorioretinopathy (CSC) and to compare two laser protocols. As per our knowledge, there are no studies comparing the two protocols of subthreshold laser. Methods: Twenty-three patients with non-resolving CSC of at least three months duration were treated with subthreshold laser (577 nm). Ten patients were treated with 5% duty cycle (group A) and 13 patients with 10% duty cycle (group B). At one month, best corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF), choroidal thickness (CT) and choroidal vascularity index (CVI) were evaluated. Results: In group A, BCVA improved from 0.508 ± 504 to 0.174 ± 0.171 (P = 0.0058), CMT improved from 349.8 ± 168.9 micrometers (μm) to 183.3 ± 70.312 μm (P = 0.0093) and SRF reduced from 202.4 ± 158.024 to 43.8 ± 46.599 μm (P = 0.0069). In group B, BCVA improved from 0.437 ± 0.426 to 0.289 ± 0.470 (P = 0.0026), CMT improved from 280.846 ± 72.668 to 196.769 ± 72.62 μm (P = 0.0002) and SRF reduced from 110.385 ± 57.687 μm to 52.538 ± 52.111 μm (P = 0.0064). No significant difference was found in BCVA and CMT between the groups (P = 0.8716 and P = 0.8523, respectively). CSC completely resolved in 50% of cases in group A and in 69.2% of cases in group B. This difference was not statistically significant (0.423); however, the odds ratio of resolution was 2.25 times more with 10% duty cycle. No change was observed on fundus autofluorescence (FAF) following laser. Conclusion: Subthreshold micropulse laser can lead to resolution of SRF in 60.87% of cases (groups A and B combined). Ten per cent duty cycle had higher odds of resolution without causing any RPE damage.

[1]  A. Sağlık,et al.  Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy. , 2020, International journal of ophthalmology.

[2]  C. Cheung,et al.  Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy , 2020, British Journal of Ophthalmology.

[3]  J. Chhablani,et al.  Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy , 2020, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  M. Pellegrini,et al.  Choroidal Vascularity Index: An In-Depth Analysis of This Novel Optical Coherence Tomography Parameter , 2020, Journal of clinical medicine.

[5]  S. Harding,et al.  Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial , 2020, The Lancet.

[6]  F. Parmeggiani,et al.  Central Serous Chorioretinopathy: Pathogenesis and Management , 2019, Clinical ophthalmology.

[7]  H. S. Kanar,et al.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up , 2018, Eye.

[8]  H. Koizumi,et al.  Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy , 2017, PloS one.

[9]  J. Vander,et al.  A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR) , 2017, Retina.

[10]  Ahmed Hosni Abd Elhamid.  Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy , 2015, Clinical ophthalmology.

[11]  Ju Young Kim,et al.  Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  Rohit Shetty,et al.  Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome , 2015, Eye.

[13]  C. Jayadev,et al.  Recent developments in retinal lasers and delivery systems , 2014, Indian journal of ophthalmology.

[14]  Gerald Liew,et al.  Central serous chorioretinopathy: a review of epidemiology and pathophysiology , 2013, Clinical & experimental ophthalmology.

[15]  T. Lai,et al.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. , 2008, Ophthalmology.

[16]  Timothy G Murray,et al.  FACTORS ASSOCIATED WITH REDUCED VISUAL ACUITY DURING LONG-TERM FOLLOW-UP OF PATIENTS WITH IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY , 2002, Retina.

[17]  A. Mudun,et al.  Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. , 1997, Ophthalmology.

[18]  L. Šiaudvytytė,et al.  Photodynamic Therapy and Central Serous Chorioretinopathy , 2012, Medical hypothesis, discovery & innovation ophthalmology journal.